Drug
ARQ 197 clinical trials
Also written ARQ 197 and Tivantinib.
- studies test it
- 43
- open now
- 0
- in phase 3
- 4
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
42 studies that test it; most in 2012 (13)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 5 |
| 2012 | 13 |
| 2013 | 3 |
| 2014 | 2 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 23
- Phase 2
- 20
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 14
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (13) · National Cancer Institute (NCI) (10) · Daiichi Sankyo (8) · Kyowa Kirin Co., Ltd. (8) · Armando Santoro, MD (2) · SCRI Development Innovations, LLC (1) · Istituto Oncologico Veneto IRCCS (1)
Often tested with
Tested in the same studies.
Erlotinib (4) · Pazopanib (1) · Omeprazole (1) · (S)-warfarin (1) · Caffeine (1) · Digoxin (1) · Midazolam (1) · Topotecan (1)
Studies
Open first, then newest update. How each study uses ARQ 197 is read from its arms, and is right about nine times in ten.
Testing it · 43
- TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)TerminatedPhase 2Istituto Oncologico Veneto IRCCSNCT02608411Written as ARQ197
- Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High SubjectsCompletedPhase 2Armando Santoro, MDNCT01892527Written as Tivantinib (ARQ197)
- Pazopanib and ARQ 197 for Advanced Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01468922Written as ARQ 197
- ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal CancerCompletedPhase 1/2Daiichi SankyoNCT01075048Written as Tivantinib
- Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior TherapyCompletedPhase 3Daiichi SankyoNCT01755767Written as Tivantinib
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerTerminatedPhase 3Daiichi SankyoNCT01244191Written as Tivantinib
- ARQ 197 for Participants With Relapsed or Refractory Germ Cell TumorsTerminatedPhase 2Daiichi SankyoNCT01055067Written as Tivantinib (ARQ 197)
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsCompletedPhase 1/2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT01178411Written as Tivantinib
- Study of the Combination of Tivantinib Plus Pemetrexed and CarboplatinCompletedPhase 1/2Armando Santoro, MDNCT02049060Written as Tivantinib
- Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedPhase 2National Cancer Institute (NCI)NCT01447914Written as Tivantinib
- Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid TumorsCompletedPhase 1Daiichi SankyoNCT01149720Written as Tivantinib (ARQ 197) Capsule
- Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer SubjectsCompletedPhase 1Daiichi SankyoNCT01517399Written as tivantinib
- Effect of Tivantinib on the QTC Interval in Cancer SubjectsCompletedPhase 1Daiichi SankyoNCT01699061Written as Tivantinib
- Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentCompletedPhase 1Daiichi SankyoNCT02150733Written as Tivantinib
- Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01696955Written as Tivantinib
- Tivantinib in Treating Patients With Metastatic Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT01519414Written as Tivantinib
- Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01654965Written as Tivantinib
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedPhase 2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT01395758Written as ARQ 197 plus erlotinib
- Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT01749384Written as Tivantinib
- A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)CompletedPhase 3Kyowa Kirin Co., Ltd.NCT02029157Written as ARQ197
See all 43 studies that test ARQ 197 →
Given in every arm · 1 — ARQ 197 is usual care beside what is tested
Codes
What other systems call ARQ 197 · ClinicalTrials.gg INT005691
- UNII (FDA) PJ4H73IL17TIVANTINIBConfirmed FDA, Wikidata
- Wikidata Q72443796ARQ 197Confirmed FDA, Wikidata
- DrugBank DB12200One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PJ4H73IL17 | TIVANTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q72443796 | ARQ 197 | Confirmed FDA, Wikidata |
| DrugBank | DB12200 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.